MXCT.L
MaxCyte, Inc. [MXCT.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MXCT.L Stock Summary
Top 10 Correlated ETFs
MXCT.L
Top 10 Correlated Stocks
MXCT.L
In the News
MXCT.L Financial details
Company Rating
Neutral
Market Cap
343.63M
Income
-35.63M
Revenue
41.29M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
143
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-15.95
Forward P/E
-
PEG
-2.84
P/S
12.44
P/B
2.27
P/C
-
P/FCF
-14.03
Quick Ratio
11.92
Current Ratio
12.87
Debt / Equity
0.08
LT Debt / Equity
0.08
-
-
EPS (TTM)
-0.3
EPS next Y
-
EPS next Q
-
EPS this Y
94.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
9.04%
Revenue last 5Y
13.81%
Revenue Q/Q
95.7%
EPS Q/Q
-
-
-
-
-
SMA20
0.62%
SMA50
-18.34%
SMA100
3.5%
Inst Own
0%
Inst Trans
0%
ROA
-12%
ROE
-14%
ROC
-0.19%
Gross Margin
88%
Oper. Margin
-123%
Profit Margin
-87%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
180.0-440.0
52W High
-28.41%
52W Low
+75%
RSI
30
Rel Volume
0.24
Avg Volume
29.47K
Volume
7.14K
Perf Week
-4.83%
Perf Month
-14.86%
Perf Quarter
28.57%
Perf Half Y
34.04%
-
-
-
-
Beta
1.04
-
-
Volatility
8.37%, 11.95%
Prev Close
1.58%
Price
315
Change
1.58%
MXCT.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.39 | 0.38 | 0.37 | 0.44 | 0.4 | |
| Net income per share | -0.24 | -0.18 | -0.22 | -0.19 | -0.37 | |
| Operating cash flow per share | -0.16 | -0.13 | -0.12 | -0.15 | -0.21 | |
| Free cash flow per share | -0.18 | -0.16 | -0.16 | -0.33 | -0.25 | |
| Cash per share | 0.3 | 0.5 | 2.81 | 2.24 | 1.63 | |
| Book value per share | 0.24 | 0.48 | 2.9 | 2.5 | 2.25 | |
| Tangible book value per share | 0.24 | 0.48 | 2.9 | 2.5 | 2.25 | |
| Share holders equity per share | 0.24 | 0.48 | 2.9 | 2.5 | 2.25 | |
| Interest debt per share | 0.14 | 0.11 | 0.07 | 0.16 | 0.18 | |
| Market cap | 91.9M | 499.46M | 923.52M | 538.39M | 492.9M | |
| Enterprise value | 83.9M | 487.67M | 881.42M | 543.42M | 465.14M | |
| P/E ratio | -6.77 | -39.51 | -45.89 | -27.22 | -13 | |
| Price to sales ratio | 4.25 | 19.09 | 27.25 | 12.16 | 11.94 | |
| POCF ratio | -10.44 | -56.87 | -86.48 | -36.42 | -22.73 | |
| PFCF ratio | -9.12 | -46.02 | -63.63 | -16.19 | -19.42 | |
| P/B Ratio | 6.76 | 15.03 | 3.51 | 2.12 | 2.12 | |
| PTB ratio | 6.76 | 15.03 | 3.51 | 2.12 | 2.12 | |
| EV to sales | 3.88 | 18.64 | 26.01 | 12.28 | 11.27 | |
| Enterprise value over EBITDA | -7.23 | -49.05 | -53.05 | -26.19 | -10.54 | |
| EV to operating cash flow | -9.53 | -55.53 | -82.53 | -36.76 | -21.45 | |
| EV to free cash flow | -8.33 | -44.93 | -60.73 | -16.34 | -18.32 | |
| Earnings yield | -0.15 | -0.03 | -0.02 | -0.04 | -0.08 | |
| Free cash flow yield | -0.11 | -0.02 | -0.02 | -0.06 | -0.05 | |
| Debt to equity | 0.53 | 0.21 | 0.02 | 0.06 | 0.08 | |
| Debt to assets | 0.24 | 0.13 | 0.02 | 0.06 | 0.07 | |
| Net debt to EBITDA | 0.69 | 1.19 | 2.53 | -0.24 | 0.63 | |
| Current ratio | 2.62 | 3.9 | 17.32 | 16.35 | 10.65 | |
| Interest coverage | -18.24 | -13.39 | -17.42 | -215.61 | 0 | |
| Income quality | 0.68 | 0.74 | 0.56 | 0.63 | 0.57 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.28 | 0.32 | 0.55 | 0.58 | 0.73 | |
| Research and developement to revenue | 0.81 | 0.68 | 0.45 | 0.44 | 0.58 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.14 | 0.24 | 0.36 | 1.25 | 0.17 | |
| Capex to revenue | -0.06 | -0.08 | -0.11 | -0.42 | -0.09 | |
| Capex to depreciation | -2.07 | -1.98 | -2.69 | -6.85 | -0.89 | |
| Stock based compensation to revenue | 0.08 | 0.09 | 0.23 | 0.27 | 0.34 | |
| Graham number | 1.15 | 1.4 | 3.81 | 3.31 | 4.31 | |
| ROIC | -0.57 | -0.28 | -0.07 | -0.08 | -0.18 | |
| Return on tangible assets | -0.45 | -0.24 | -0.07 | -0.07 | -0.14 | |
| Graham Net | 0.08 | 0.32 | 2.67 | 2.06 | 1.38 | |
| Working capital | 15.11M | 33.64M | 254.82M | 236.84M | 172.34M | |
| Tangible asset value | 13.6M | 33.23M | 262.9M | 253.97M | 232.17M | |
| Net current asset value | 8.07M | 26.7M | 249.21M | 219.58M | 154.09M | |
| Invested capital | 0.53 | 0.21 | 0.02 | 0.06 | 0.08 | |
| Average receivables | 4.07M | 4.21M | 6.02M | 10.22M | 9.67M | |
| Average payables | 3.11M | 1.49M | 1.36M | 1.18M | 637.4K | |
| Average inventory | 2.97M | 4.01M | 4.76M | 6.89M | 10.4M | |
| Days sales outstanding | 54.77 | 72.14 | 74.06 | 111.88 | 51.08 | |
| Days payables outstanding | 305.15 | 117.43 | 182.16 | 38.07 | 57.19 | |
| Days of inventory on hand | 540.64 | 569.31 | 520.83 | 614.31 | 941.29 | |
| Receivables turnover | 6.66 | 5.06 | 4.93 | 3.26 | 7.15 | |
| Payables turnover | 1.2 | 3.11 | 2 | 9.59 | 6.38 | |
| Inventory turnover | 0.68 | 0.64 | 0.7 | 0.59 | 0.39 | |
| ROE | -1 | -0.38 | -0.08 | -0.08 | -0.16 | |
| Capex per share | -0.02 | -0.03 | -0.04 | -0.18 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.12 | 0.09 | 0.09 | 0.08 | 0 | |
| Net income per share | -0.03 | -0.09 | -0.1 | -0.11 | 0 | |
| Operating cash flow per share | -0.06 | -0.04 | -0.1 | -0.08 | 0 | |
| Free cash flow per share | -0.08 | -0.06 | -0.1 | -0.09 | 0 | |
| Cash per share | 2.23 | 2.27 | 2.1 | 1.84 | 0 | |
| Book value per share | 2.49 | 2.51 | 2.34 | 2.26 | 0 | |
| Tangible book value per share | 2.49 | 2.51 | 2.34 | 2.26 | 0 | |
| Share holders equity per share | 2.49 | 2.51 | 2.34 | 2.26 | 0 | |
| Interest debt per share | 0.16 | 0.14 | 0.16 | 0.16 | 0 | |
| Market cap | 540.6M | 477.9M | 454.51M | 318.84M | 0 | |
| Enterprise value | 545.63M | 456.32M | 416.16M | 285.75M | -27.76M | |
| P/E ratio | -47.11 | -13.92 | -10.81 | -7.08 | 0 | |
| Price to sales ratio | 43.51 | 55.72 | 50.26 | 39.83 | 0 | |
| POCF ratio | -88.82 | -110.51 | -44.98 | -38.7 | 0 | |
| PFCF ratio | -65.28 | -81.24 | -42.83 | -35.59 | 0 | |
| P/B Ratio | 2.13 | 1.93 | 1.89 | 1.37 | 0 | |
| PTB ratio | 2.13 | 1.93 | 1.89 | 1.37 | 0 | |
| EV to sales | 43.92 | 53.21 | 46.02 | 35.7 | -1.77 | |
| Enterprise value over EBITDA | -140.67 | -37.36 | -34.54 | -22.2 | 3.97 | |
| EV to operating cash flow | -89.65 | -105.52 | -41.18 | -34.69 | -28.28 | |
| EV to free cash flow | -65.89 | -77.57 | -39.22 | -31.9 | -414.99 | |
| Earnings yield | -0.01 | -0.02 | -0.02 | -0.04 | 0 | |
| Free cash flow yield | -0.02 | -0.01 | -0.02 | -0.03 | 0 | |
| Debt to equity | 0.06 | 0.07 | 0.07 | 0.07 | 0.08 | |
| Debt to assets | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | |
| Net debt to EBITDA | -1.3 | 1.77 | 3.18 | 2.57 | 3.97 | |
| Current ratio | 16.35 | 14.81 | 17.92 | 12.87 | 10.65 | |
| Interest coverage | -619.28 | 5.74 | 0 | 0 | 0 | |
| Income quality | 1.27 | 0.4 | 0.96 | 0.73 | -0.19 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.45 | 0.87 | 0.85 | 0.85 | 0.52 | |
| Research and developement to revenue | 0.46 | 0.71 | 0.63 | 0.78 | 0.37 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.36 | 0.36 | 0.05 | 0.09 | -0.93 | |
| Capex to revenue | -0.18 | -0.18 | -0.06 | -0.09 | -0.06 | |
| Capex to depreciation | -2.39 | -1.62 | -0.49 | -0.67 | -0.83 | |
| Stock based compensation to revenue | 0.25 | 0.38 | 0.39 | 0.45 | 0.23 | |
| Graham number | 1.25 | 2.21 | 2.32 | 2.35 | 0 | |
| ROIC | -0.01 | -0.04 | -0.05 | -0.05 | -0.03 | |
| Return on tangible assets | -0.01 | -0.03 | -0.04 | -0.04 | -0.02 | |
| Graham Net | 2.05 | 2.05 | 1.91 | 1.64 | 0 | |
| Working capital | 236.84M | 229.8M | 223.41M | 197.69M | 172.34M | |
| Tangible asset value | 253.97M | 247.82M | 240.98M | 233.38M | 232.17M | |
| Net current asset value | 219.58M | 212.71M | 206.4M | 180.99M | 154.09M | |
| Invested capital | 0.06 | 0.07 | 0.07 | 0.07 | 0.08 | |
| Average receivables | 10.89M | 11.43M | 8.45M | 7.89M | 6.97M | |
| Average payables | 1.31M | 2.02M | 2.55M | 1.02M | 594.8K | |
| Average inventory | 8.25M | 9.42M | 10.64M | 11.78M | 12.38M | |
| Days sales outstanding | 98.28 | 97.5 | 75.72 | 91.82 | 33.2 | |
| Days payables outstanding | 30.95 | 315.25 | 104.86 | 50.66 | 42.51 | |
| Days of inventory on hand | 499.37 | 924.03 | 720.96 | 1.42K | 699.64 | |
| Receivables turnover | 0.92 | 0.92 | 1.19 | 0.98 | 2.71 | |
| Payables turnover | 2.91 | 0.29 | 0.86 | 1.78 | 2.12 | |
| Inventory turnover | 0.18 | 0.1 | 0.12 | 0.06 | 0.13 | |
| ROE | -0.01 | -0.03 | -0.04 | -0.05 | -0.02 | |
| Capex per share | -0.02 | -0.02 | 0 | -0.01 | 0 |
MXCT.L Frequently Asked Questions
What is MaxCyte, Inc. stock symbol ?
MaxCyte, Inc. is a US stock , located in Rockville of Md and trading under the symbol MXCT.L
What is MaxCyte, Inc. stock quote today ?
MaxCyte, Inc. stock price is $315 today.
Is MaxCyte, Inc. stock public?
Yes, MaxCyte, Inc. is a publicly traded company.
Company Profile
- Volume Average 29.47K
- Market Capitalization 343.63M
- Employee 143
- CEO Mr. Maher Masoud
- Headquarters Rockville,MD,US
- IPO Date 2016-03-29
-
Website
https://maxcyte.com 
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
